Literature DB >> 12913943

Fibromyalgia syndrome in an Amish community: a controlled study to determine disease and symptom prevalence.

Kevin P White1, John Thompson.   

Abstract

OBJECTIVES: To estimate the point prevalence of fibromyalgia syndrome (FM) in Amish adults and to compare the prevalence of chronic pain, chronic widespread pain, FM, chronic fatigue, and debilitating fatigue in the Amish versus non-Amish rural and urban controls. The a priori assumption was that, if litigation and/or compensation availability have major effects on FM prevalence, then FM prevalence in the Amish should approach zero.
METHODS: We surveyed 242 Amish adults in a small rural community southeast of London, Ontario, Canada. Individuals were screened using a validated screening instrument. Those reporting chronic, widespread pain were examined for FM using published classification criteria. Amish results were compared to results collected in a random telephone survey of 492 non-Amish adults living in rural Southwestern Ontario and 3395 non-Amish adults previously surveyed in London.
RESULTS: Pain lasting at least one week in the preceding 3 months was reported by 34.3% of the Amish; pain in the upper extremities by 25.4%, in the lower extremities by 22.5%, and in the trunk by 28.1%. Twenty-six (15 women, 11 men) reported chronic, widespread pain. Eleven FM cases were confirmed among women (age adjusted point prevalence, p = 10.4%) and 2 among men (p = 3.7%) for an overall age and sex adjusted prevalence of 7.3% (95% CI 5.3, 9.7); this was both statistically greater than zero (p < 0.0001) and greater than in either control population (both p < 0.05).
CONCLUSION: FM is relatively common among the Amish.

Entities:  

Mesh:

Year:  2003        PMID: 12913943

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Worldwide epidemiology of fibromyalgia.

Authors:  Luiz Paulo Queiroz
Journal:  Curr Pain Headache Rep       Date:  2013-08

Review 2.  [Fibromyalgia--an update].

Authors:  W Brückle; H Zeidler
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

3.  Duloxetine for the management of fibromyalgia syndrome.

Authors:  Beth A Scholz; Cara L Hammonds; Chad S Boomershine
Journal:  J Pain Res       Date:  2009-07-21       Impact factor: 3.133

4.  Newer treatments for fibromyalgia syndrome.

Authors:  Richard E Harris; Daniel J Clauw
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 5.  Vitamin D in Fibromyalgia: A Causative or Confounding Biological Interplay?

Authors:  Spyridon Karras; Eleni Rapti; Stauros Matsoukas; Kalliopi Kotsa
Journal:  Nutrients       Date:  2016-06-04       Impact factor: 5.717

Review 6.  A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population.

Authors:  Kathryn E Mansfield; Julius Sim; Joanne L Jordan; Kelvin P Jordan
Journal:  Pain       Date:  2016-01       Impact factor: 7.926

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.